Search company, investor...

Predict your next investment

Venture Capital
innospark.vc

Investments

25

Funds

1

About Innospark Ventures

Innospark Ventures is a Boston-based early-stage venture capital firm, investing in the AI-driven economy.

Headquarters Location

Boston, Massachusetts, 02116,

United States

Want to inform investors similar to Innospark Ventures about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Latest Innospark Ventures News

Bengaluru-Based Company Kreedo Raises $2.3 Mn In Pre Series A Funding

Dec 22, 2022

Kreedo Early Childhood Solutions, a Bengaluru based company that provides end-to-end solutions to transform the way early learning is delivered, has raised $2.3 Million in Pre Series A Funding. The round was led by Switzerland based UBS Optimus Foundation, Spectrum Impact, Gray Matters Capital and  1Crowd, with participation from Innospark Ventures, IIM-CAN and The Chennai Angels. The latest round of funding will be used towards accelerating Kreedo’s next phase of growth and expansion. Kreedo is transforming the learning experiences of children in these schools via a structured and immersive learning process through its 6T Learning Framework that has Play Based Learning at its core and includes Toys, Technology, Theory (books), Teacher Training, Timetable, and Teamwork (peer learning). By setting up activity labs and consistently training teachers, Kreedo offers a comprehensive solution that empowers schools to significantly improve learning outcomes. Commenting on the investment, Mridula Shridhar, CEO, Kreedo, said, “Our vision is to democratize quality early education. We have an overwhelming response from our partner schools who are looking for the most affordable and simplest way to improve foundational learning. The new round of funding will enable us to take Kreedo to 7000+ schools across multiple cities in India” Share this article:

Innospark Ventures Investments

25 Investments

Innospark Ventures has made 25 investments. Their latest investment was in Antiverse as part of their Seed VC - II on March 3, 2023.

CBI Logo

Innospark Ventures Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

3/1/2023

Seed VC - II

Antiverse

$3M

Yes

3

2/1/2023

Seed VC

Starling Medical

$3.4M

Yes

1

9/8/2022

Seed VC - II

Dyania Health

$5M

Yes

1

7/4/2022

Seed VC

Subscribe to see more

$99M

Subscribe to see more

10

6/7/2022

Seed VC - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

3/1/2023

2/1/2023

9/8/2022

7/4/2022

6/7/2022

Round

Seed VC - II

Seed VC

Seed VC - II

Seed VC

Seed VC - II

Company

Antiverse

Starling Medical

Dyania Health

Subscribe to see more

Subscribe to see more

Amount

$3M

$3.4M

$5M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

3

1

1

10

10

Innospark Ventures Fund History

1 Fund History

Innospark Ventures has 1 fund, including Innospark Ventures Fund.

Closing Date

Fund

Fund Type

Status

Amount

Sources

Innospark Ventures Fund

$100M

1

Closing Date

Fund

Innospark Ventures Fund

Fund Type

Status

Amount

$100M

Sources

1

Innospark Ventures Team

1 Team Member

Innospark Ventures has 1 team member, including current Managing Director, Venkat Srinivasan.

Name

Work History

Title

Status

Venkat Srinivasan

Managing Director

Current

Name

Venkat Srinivasan

Work History

Title

Managing Director

Status

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.